Skip to Main Content
Yale Cancer Center
YSM Home

INFORMATION FOR

Jiyeon Kim, PhD

Assistant Professor of Urology and Cellular & Molecular Physiology
DownloadHi-Res Photo

Contact Info

jiyeon.kim1@yale.edu

Yale School of Medicine

310 Cedar St., BML

New Haven, Connecticut 06519

United States

About

Titles

Assistant Professor of Urology and Cellular & Molecular Physiology

Biography

Dr. Kim is a basic research scientist in the Department of Urology with a joint appointment in the Department of Cellular and Molecular Physiology. She received her PhD from the Department of Molecular Cancer Biology at Duke University under the supervision of Dr. Sally Kornbluth, and her postdoctoral training from Dr. Ralph DeBerardinis at UT-Southwestern Medical Center. Before coming to Yale, she was The Kim lab is focused on understanding how metabolic alterations elicit dependencies and liabilities in certain signaling pathways and how we can target the pathway as cancer’s Achilles' heel. 

The lab has been actively applying metabolic flux analysis to panels of cancer cell lines with various mutations to understand the full breadth of metabolic diversity in cancer. These studies are complemented by in vivo analyses of cancer metabolism in mice, and by translational efforts designed to understand and exploit the metabolic idiosyncrasies of tumor cells.


Last Updated on December 22, 2022.

Appointments

Other Departments & Organizations

Education & Training

Postdoctoral fellow
UT-Southwestern Medical Center (2018)
PhD
Duke University, Molecular Cancer Biology (2012)

Research

Research at a Glance

Publications Timeline

A big-picture view of Jiyeon Kim's research output by year.
10Publications

Publications

2022

2020

  • The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer.
    Kim J, Lee HM, Cai F, Ko B, Yang C, Lieu EL, Muhammad N, Rhyne S, Li K, Haloul M, Gu W, Faubert B, Kaushik AK, Cai L, Kasiri S, Marriam U, Nham K, Girard L, Wang H, Sun X, Kim J, Minna JD, Unsal-Kacmaz K, DeBerardinis RJ. The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer. Nat Metab 2020, 2: 1401-1412. PMID: 33257855, DOI: 10.1038/s42255-020-00316-0.
    Peer-Reviewed Original Research
  • Amino acids in cancer.
    Lieu EL, Nguyen T, Rhyne S, Kim J. Amino acids in cancer. Exp Mol Med 2020, 52: 15-30. PMID: 31980738, DOI: 10.1038/s12276-020-0375-3.
    Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements

2019

2017

  • CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells.
    Kim J, Hu Z, Cai L, Li K, Choi E, Faubert B, Bezwada D, Rodriguez-Canales J, Villalobos P, Lin YF, Ni M, Huffman KE, Girard L, Byers LA, Unsal-Kacmaz K, Peña CG, Heymach JV, Wauters E, Vansteenkiste J, Castrillon DH, Chen BPC, Wistuba I, Lambrechts D, Xu J, Minna JD, DeBerardinis RJ. CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells. Nature 2017, 546: 168-172. PMID: 28538732, DOI: 10.1038/nature22359.
    Peer-Reviewed Original Research

2016

2013

2012

2009

Academic Achievements & Community Involvement

Honors

  • honor

    Innovation Award

    02/01/2022National AwardAmerican Lung Association
  • honor

    Research Scholar Grant

    01/01/2022National AwardAmerican Cancer Society
  • honor

    V Scholar Award

    07/01/2020National AwardV Foundation
  • honor

    K22 Transition Career Development Award

    04/01/2019National AwardNational Cancer Institute
  • honor

    Cancer Discovery Award

    01/01/2019National AwardAmerican Lung Association

Get In Touch

Contacts

Email
Mailing Address

Yale School of Medicine

310 Cedar St., BML

New Haven, Connecticut 06519

United States

Locations